Church of PeptidesSearch
Portrait of Semaglutide
New Disciples · approved 2017 onward

Semaglutide

The Long Table

Denmark

Semaglutide activates the GLP-1 receptor, helping regulate blood glucose and appetite. It appears in several approved medicines with different formulations and indications; the molecule’s name alone does not tell you which benefits or warnings apply.

Evidence ladder: Approved human use Approved human use · product-specific labels Educational record
Classification New Disciples
Evidence summary Approved human use · product-specific labels
Origin Denmark
Scientific record

What the evidence says

Established role or proposed benefit

  • Approved products have distinct diabetes, chronic weight-management, and risk-reduction indications.
  • Improves glucose-dependent signaling and can reduce appetite.

Side effects, risks, and limits

  • Gastrointestinal reactions are common and can be serious.
  • Product identity, labeled indication, contraindications, and compounded-product distinctions are essential.
Doctide’s verdict

Doctide gives the Long Table several place cards: one molecule, multiple product records. Its substantial clinical evidence earns attention, but each claimed benefit still needs the matching formulation, studied population, and label.

Documented history

Where the real story begins

FDA first approved injectable semaglutide as Ozempic in December 2017. Oral semaglutide followed as Rybelsus in September 2019, and Wegovy received its original approval in June 2021. These milestones describe separate products, followed by later changes to their individual labels. Historical source.

Denmark · approved 2017 onward
Book of the Canon · comic scripture

The laboratory legend

Semaglutide slowed the banquet, lowered the sugar banner, and stayed long after the other guests left. Doctide assigned an entire clerk to keep her product labels separate.

This bold passage is invented comedy, not scientific or historical fact.
Editorial recordProfile editorial revision: October 4, 2026 Prepared under the Church of Peptides evidence standard Editorial review: Church of Peptides Independent clinical review: none to date Content evidence reviewed: September 17, 2026
Evidence ledger

Sources

  1. FDA Drugs@FDA · Ozempic application record
  2. FDA Drugs@FDA · Wegovy application record
  3. FDA Drugs@FDA · Rybelsus application record
  4. STEP 1 · randomized human trial · NEJM 2021
  5. FDA · concerns with unapproved GLP-1 products · updated 2026

Fiction disclosure: The bold laboratory legend is invented. The historical and scientific sections are factual summaries; no invented connective events were added.

Educational entertainment only. Not medical advice, diagnosis, dosing guidance, or a recommendation to obtain or use a product.

The Book of Trials

Follow the research journey

Join Subject One for six short chapters, from laboratory and animal studies to human trials and today’s evidence.

Read the Semaglutide journey →